"Interesting data; I wonder what the health economists at NICE would say about this model and data. As you may know already we are having major problems accessing Sativex in the UK for MSers under our care. The bottom line with Sativex is that it is not a drug for everyone; only about 40-50% of MSers respond and even then some can't tolerate the drug because of side effects. Have any of you responded to the drug?"